# Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

> **NCT03681457** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** LJN452

## Key facts

- **NCT ID:** NCT03681457
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2019-09-25
- **Final completion:** 2019-09-25
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681457, "Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03681457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*